Kay-Oliver Kliche, MD , Medical Director of Hematology and Oncology, Medical Affairs PRA Health Sciences shares his thoughts on the brief history of oncology genomics research and discusses its current achievements as well as the future direction of cancer genomics.
Key points that were highlighted include
> Regulatory concerns cancer genomics clinical research
> Assay determination and trial design framework limitations
> Incorporation of epigenetic changes in trials strategies etc
Download this white paper on Cancer Genomics over here
If you are in cancer genomics research and like to find out more about how you can further your research or discuss collaboration opportunities, network with PRA at the BioPharma Asia Convention 2015 exhibition (24 – 25 March 2015).